in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)

Slides:

Advertisements

Similar presentations

Figure 2 Electromechanical properties of OIHPs

Advertisements

Figure 6 Selected examples of TERS applications in material systems

Figure 3 Life expectancy at birth in all countries included

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 4 The gut microbiota directly influences T-cell differentiation

Nat. Rev. Endocrinol. doi: /nrendo

Figure 4 Activation of clopidogrel via cytochrome P450

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 5 Lipid droplet consumption

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Worldwide incidence of CCA

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Global epidemiology of common Clostridium difficile ribotypes

Figure 2 The microbiome–gut–brain axis

Figure 1 Organs involved in coeliac-disease-associated autoimmunity

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Biosimilar development process

Figure 2 Effect of PPIs on gastric physiology

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 4 Giant lipid droplet formation

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Combination therapy for HCC

Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.

Figure 1 Definition and concept of ACLF

Figure 1 Functions, features and phenotypes of HSCs in normal and diseased livers Figure 1 | Functions, features and phenotypes of HSCs in normal and diseased.

Figure 1 Host range of hepatitis E virus

Figure 2 Switching of biologic agents and biosimilars

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

to the liver and promote patient-derived xenograft tumour growth

Figure 7 Example colonic high-resolution manometry

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Cardiovascular risk and disease across the life-course

Figure 1 Environmental factors contributing to IBD pathogenesis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Clinical algorithms in the management of NASH and diabetes mellitus Figure 3 | Clinical algorithms in the management of NASH and diabetes mellitus.

Alcohol and related health issues in China: action needed

Figure 2 13C-octanoic acid gastric emptying breath test

Figure 1 Median coverage and distribution by

Figure 2 Global cost of HF per capita in 2012

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Possible therapeutic targets to decrease hepatic steatosis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Combining population-wide and high-risk strategies

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Brain–gut axis Brain–gut axis. Schematic of the brain–gut axis, including inputs from the gut microbiota, the ENS, the immune system and the external.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Assessment of colonic transit time with radiopaque markers

Figure 5 Systems biological model of IBS

Figure 2 Dzyaloshinskii–Moriya interactions

Figure 4 Local species pools that contribute to the

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Lifelong influences on the gut microbiome from

Figure 2 Classifications and appearance of CCAs

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Enhanced imaging techniques and autofluorescence endoscopy for Barrett oesophagus Figure 2 | Enhanced imaging techniques and autofluorescence.

Figure 2 Diffusio-osmotic process for osmotic energy conversion

Presentation transcript:

in the UK (1961–2012), France (1961–2014) and Italy (1961–2010) Figure 2 Litres of pure alcohol (recorded) consumed per person aged 15 years and over in the UK (1961–2012), France (1961–2014) and Italy (1961–2010) Figure 2 | Litres of pure alcohol (recorded) consumed per person aged 15 years and over in the UK (1961–2012), France (1961–2014) and Italy (1961–2010). Adapted with permission from the Global Information System on Alcohol and Health, WHO139,140,141. Adapted with permission from the Global Information System on Alcohol and Health, WHO Gilmore, W. et al. (2016) Alcohol: taking a population perspective Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2016.70